IRAK4 and primary central nervous system lymphoma: Targeted drugs such as Bruton’s tyrosine kinase (BTK) inhibitors, interleukin-1 receptor-associated kinase-4 inhibitors, and immunomodulators including lenalidomide and pomalidomide had also show certain efficacy in central nervous system lymphoma.